Fedenia Advisers’s AbCellera Biologics ABCL Stock Holding History

Fedenia Advisers’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-40,000	Closed	-$314K	–	123
2026 Q2	$314K	Buy	+40,000	New	+$196K	0.07%	101

Other funds holding ABCL

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Guardian Partners Toronto, Canada $1.13B AUM 28.37% 1-Year Est. Return

Citizens Financial Group Providence, Rhode Island $8.58B AUM 20.32% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return

DKM Wealth Management Stockton, California $158M AUM 11.62% 1-Year Est. Return

Lantern Wealth Advisors Melville, New York $232M AUM 16.88% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Fedenia Advisers's ABCL Position: Q3 2026 in Review

Fedenia Advisers sold out of AbCellera Biologics (ABCL) in Q3 2026, closing a stake of 40,000 shares — an estimated $314K sold.

Fedenia Advisers first reported a position in ABCL in Q2 2026 and held it in 1 quarter. The position peaked at $314K in Q2 2026. 15 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

Fedenia Advisers reported no remaining AbCellera Biologics position as of Q3 2026 after selling out during the quarter.
Fedenia Advisers sold 40,000 AbCellera Biologics shares in Q3 2026, an estimated $314K.
Fedenia Advisers first reported a position in AbCellera Biologics in Q2 2026 and held it in 1 quarter.
Fedenia Advisers's AbCellera Biologics position peaked at $314K in Q2 2026.
15 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Fedenia Advisers's 13F filing for Q3 2026, filed 22 Oct 2026.